MALOTILATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C12H16O4S2
Molecular Weight	288.383
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)OC(=O)C(C(=O)OC(C)C)=C1SC=CS1

InChI

InChIKey=YPIQVCUJEKAZCP-UHFFFAOYSA-N

InChI=1S/C12H16O4S2/c1-7(2)15-10(13)9(11(14)16-8(3)4)12-17-5-6-18-12/h5-8H,1-4H3

HIDE SMILES / InChI

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/2544209
Curator's Comment: description was created based on several sources, including https://www.medchemexpress.com/malotilate.html

Malotilate (NKK-105) is a drug used in the treatment of liver disease. Malotilate selectively inhibits the 5-lipoxygenase. Malotilate prevented increases in serum markers of type III and IV collagen synthesis as well as accumulation of the collagens, laminin and fibronectin in the liver.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Arachidonate 5-lipoxygenase 49 Target ID: CHEMBL215 Sources: http://www.ncbi.nlm.nih.gov/pubmed/2537738	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Alcoholic liver disease 2 Sources: http://www.ncbi.nlm.nih.gov/pubmed/2544209	Primary		Phase II 1132	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[Protective effect of malotilate (diisopropyl 1,3-dithiol-2-ylidenemalonate) on chemical-induced hepatotoxicity].	1986 Aug	3795300
Modulation of the reductive metabolism of halothane by microsomal cytochrome b5 in rat liver.	1987 Dec 7	3689822
[Acute alcoholic hepatitis: treatments].	2001 Jun 9	11433695
[Effect of tanshinone IIA on CCl4-induced liver fibrosis in rats].	2002 Jan	12583240
Specific siRNA targeting the receptor for advanced glycation end products inhibits experimental hepatic fibrosis in rats.	2008 Apr	19325776
Matrix metalloproteinase gene delivery for liver fibrosis.	2008 Feb	17577645
bFGF regulates PI3-kinase-Rac1-JNK pathway and promotes fibroblast migration in wound healing.	2010 Aug 17	20808927

Patents

Sample Use Guides

In Vivo Use Guide

Six patients in an open 6-month trial received malotilate 200 mg t.i.d. for 2 months and 400 mg t.i.d. for 4 months

Route of Administration: Oral

In Vitro Use Guide

Effects of NKK-105 (MALOTILATE) against lipid peroxidation of microsomes by CCl4 are investigated, in vitro. NKK-105 had no effect on microsomal lipid peroxidation. With the microsomal fraction was preincubated with NKK-105 before adding CCl4, the lipid peroxidation induced with CCl4 was almost prevented by NKK-105.

Name

Type

Language

MALOTILATE

Official Name

English

KANTEC

Brand Name

English

MALOTILATE [MART.]

Common Name

English

PROPANEDIOIC ACID, 2-(1,3-DITHIOL-2-YLIDENE)-, 1,3-BIS(1-METHYLETHYL) ESTER

Common Name

English

HEPATION

Brand Name

English

NKK-105

Code

English

MALOTILATE [MI]

Common Name

English

PROPANEDIOIC ACID, 1,3-DITHIOL-2-YLIDENE-, BIS(1-METHYLETHYL) ESTER

Common Name

English

MALOTILATE [JAN]

Common Name

English

malotilate [INN]

Common Name

English

Malotilate [WHO-DD]

Common Name

English

MALOTILATE [USAN]

Common Name

English

DIISOPROPYL 1,3-DITHIOL-2-YLIDENEMALONATE

Systematic Name

English

NKK 105

Code

English

Code System Code Type Description

SMS_ID

100000081740